Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes

NCT02058160 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

736

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: Insulin glargine/lixisenatide (HOE901/AVE0010)
DRUG: Insulin glargine (HOE901)
DRUG: Metformin (Background Drug)

Sponsor

Sanofi